#antiretrovirals

Health researchers are testing the flying bots in remote rural regions and congested urban areas alike.

A new global alliance launches to end AIDS in children by 2030. Currently, only half of children with HIV are on lifesaving treatment.

People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.

People with untreated depression are more likely to be nonadherent to antiretroviral treatment, but antidepressants remove the disparity.

So far, it appears that people on antiretroviral treatment with well-controlled HIV do not have worse monkeypox outcomes.

The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.

The every-other-month schedule of injectable cabotegravir plus rilpivirine enables some people to take HIV treatment just six times a year.

In recent years, myocardial infarction risk rose for HIV-positive people while falling for HIV-negative individuals.

Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.

New HIV treatment guidelines boost TAF and dolutegravir but warn about Trogarzo and advise against Cabenuva for pregnant people.

A study showed that as HIV treatment expanded, teens lost fewer parents to the virus.

Black and Latino men who have sex with men are not seeing the same improvements as white men, but innovative approaches can help.

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

HIV stigma and worries about disclosure were also associated with lower odds of taking treatment as prescribed.

The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.

These encouraging results do not apply, however, to people who remain undiagnosed.